Summary: Researchers have identified an alternative biological pathway that explains how GLP-1 receptor agonists can ease psychiatric symptoms. Using mouse models of chronic stress, the team traced how the diabetes and weight-loss drug liraglutide influences behavior by acting through the gut microbiome rather than directly on brain receptors.
The study found that liraglutide concentrates in the intestine and stimulates a marked increase of the gut bacterium Lactobacillus delbrueckii. This bacterium produces diacylglycerol, a precursor that the host converts into the endocannabinoid 2-arachidonoylglycerol (2-AG). Elevated 2-AG levels dampen overactive stress-related neural circuits, reducing depressive-like behaviors in mice.
Key Facts
- Revising a brain-centric view: Clinical data on GLP-1 drugs have been mixed—some studies report antidepressant effects while others suggest mood risks. The prevailing assumption was that these drugs acted by entering the brain and binding central GLP-1 receptors; this study proposes a non-canonical, gut-mediated mechanism.
- Intestinal accumulation, not brain penetration: In mice, systemically administered liraglutide was found to build up mainly in intestinal tissues rather than in the brain.
- Genetic receptor knockout evidence: Liraglutide preserved antidepressant and anti-anxiety activity in mice lacking GLP-1 receptors, indicating that central GLP-1 receptor signaling is not required for these behavioral effects.
- Microbiome dependence: The drug’s behavioral benefits disappeared when mice received broad‑spectrum antibiotics that depleted their gut microbiota, demonstrating that live gut microbes are essential to the effect.
- Lactobacillus delbrueckii expansion: Fecal metagenomic analysis showed that L. delbrueckii was the most prominently increased species after liraglutide treatment, and its abundance closely tracked the degree of behavioral improvement.
- Endocannabinoid pathway: L. delbrueckii produces diacylglycerol, which the host converts into the endocannabinoid 2-AG. Raised 2-AG levels act to normalize hyperactive neuronal activity in stress-related brain regions.
- Implications for targeted probiotics: The findings suggest new therapeutic possibilities, such as developing L. delbrueckii-based probiotic interventions to help treat depression that co-occurs with metabolic conditions like obesity or type 2 diabetes.
- Limitations and next steps: The work was performed in male mice only; the authors stress the need for studies including female subjects and eventual human trials to confirm whether the microbiome–endocannabinoid mechanism operates across sexes and translates to people.
Source: Cell Press
Overview
Some patients prescribed GLP-1 agonists for diabetes or weight management report improved mood and reduced depressive symptoms. To investigate how these metabolic drugs might influence mental health, researchers conducted mechanistic experiments in stressed mouse models and traced the drug’s effects from gut to brain.
The research, published in Cell Host & Microbe, centered on liraglutide (brand names Victoza and Saxenda). Rather than crossing into the brain in significant amounts, liraglutide was detected predominantly in intestinal tissue. Behavioral testing showed antidepressant-like and anxiolytic effects even in animals genetically engineered to lack GLP-1 receptors, indicating an alternative route of action.
When the team depleted the gut microbiome using broad‑spectrum antibiotics, liraglutide’s behavioral effects were abolished. Fecal sequencing then revealed that liraglutide substantially increased the abundance of Lactobacillus delbrueckii. Further metabolic analyses linked that bacterial growth to production of diacylglycerol, which is converted by the host into 2‑arachidonoylglycerol (2‑AG), an endogenous endocannabinoid known to modulate neuronal excitability in emotional processing centers.
Additional experiments showed that fecal microbiota transplantation from liraglutide-treated donors, as well as direct colonization with L. delbrueckii, replicated the antidepressant effects. Together, these results define a microbiota‑endocannabinoid metabolic pathway that mediates liraglutide’s mood-regulating properties in mice.
Key Questions Answered:
A: The drug reshapes the gut microbiome. Liraglutide accumulates in the intestine and promotes growth of Lactobacillus delbrueckii. That bacterium produces metabolites that the host converts into an endocannabinoid, 2-AG, which then reduces hyperactivity in stress-related brain circuits.
A: The link is the endocannabinoid 2-AG. L. delbrueckii produces diacylglycerol, which is converted by the host into 2-AG. Elevated 2-AG signals to brain regions involved in emotional processing and lowers neural hyperactivity associated with anxiety and depression.
A: No. These findings come from controlled experiments in mouse models. Human clinical trials are needed before changing treatment recommendations. The study does, however, point toward future precision-medicine approaches—potentially using targeted probiotics to activate the same gut‑brain pathway without systemic metabolic drugs.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The cited journal paper was reviewed in full.
- Additional context was added by editorial staff.
About this neuropharmacology and depression research news
Author: Julia Grimmett
Source: Cell Press
Contact: Julia Grimmett – Cell Press
Image: Image credit: Neuroscience News
Original Research: Open access. “Microbiota-driven gut–brain signaling underlies antidepressant effects of a GLP-1 analog” by Liang Bian et al., Cell Host & Microbe. DOI: 10.1016/j.chom.2026.05.003
Abstract
Microbiota-driven gut–brain signaling underlies antidepressant effects of a GLP-1 analog
Although GLP-1 receptor agonists are widely used to treat metabolic disease, their neuropsychiatric effects are not fully understood and remain controversial. This study demonstrates that liraglutide reduces depressive behavior through a gut‑brain pathway that functions independently of GLP-1 receptor signaling. Using pharmacological antagonists and Glp1r knockout mice, researchers showed that liraglutide preserved antidepressant efficacy even without central GLP-1 receptor activity, while depletion of the gut microbiota abolished the effect.
Multi-omics analyses identified Lactobacillus delbrueckii as markedly increased after liraglutide treatment. L. delbrueckii restored levels of the endocannabinoid 2-AG by producing diacylglycerol precursors. Elevated 2-AG mediated the antidepressant outcome by normalizing excessive neuronal activity in emotional processing regions. Fecal microbiota transplantation from liraglutide-treated donors or direct colonization with L. delbrueckii reproduced the behavioral benefits. These results reveal a non-canonical mechanism for GLP-1 analogs and highlight a specific microbiota–endocannabinoid metabolic pathway as a potential therapeutic target for depression.